Boston Scientific

Q3 2026
Speakers

Oct 28, 2026 · 61 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good morning and welcome to the Boston Scientific Third Quarter 2026 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two.

Please note this event is being recorded. I would now like to turn the conference over to Lauren Tangler, Vice President Investor Relations. Please go ahead.

Passages & reports (2)
  • Good morning and welcome to the Boston Scientific Third Quarter 2026 earnings call. All pa…
  • to ask questions. To ask a question, you may press star then one on your telephone keypad.…

Speaker 1

Unverified voice label

Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer, ?and John Monson, Executive Vice President and Chief Financial Officer. During the QA session, Mike and John will be joined by Joe Fitzgerald, Executive Vice President and Group President, Cardiology, and our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q3 2026 results, which included reconciliations ?of the non-GAP measures used in this release.

The release, as well as reconciliations of the non-GAP measures used in today's call, can be found on the investor relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic revenue further excludes certain acquisitions and
divestitures for which there is less than a full period of comparable net sales. Guidance excludes our previously announced agreement to acquire Penumbra, which we expect to close in early 2027.

For more information, please refer to the Q3 financial and operating highlights deck, which may be found on the investor relations section of our
website. On this call, all references to sales and revenue are organic and relative growth is compared to the same quarter of prior year, unless otherwise specified. This call contains forward-looking statements regarding, among other things, our financial performance, business plans, market expectations, and product performance and development.

These statements are based on our current
beliefs using information available to us as of today's date and not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect or certain risks or uncertainties materialize, actual results could vary materially from those projected by the forward looking statements. Factors that may cause such differences are discussed in the earnings release we issued earlier this morning and our periodic reports and other filings with the FEC, including the risk factor section of our most recent annual report on the Form 10K.

Boston Scientific disclaims any intention or obligation to update these forward looking statements except as required by law. In
addition, this call does not constitute an offer to sell or the solicitation of an offer to buy any securities or solicitation ?of any vote or approval in connection with the proposed transaction with Penumbra. Boston Scientific has filed with the SEC a registration statement on Form S4 containing a proxy statement of Penumbra and a prospectus of Boston Scientific that contains important information ?about Penumbra, Boston Scientific, the proposed transaction, and related matters.

At this point, I'll turn it over to Mike.

Passages & reports (14)
  • Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Ch…
  • and
  • John Monson, Executive Vice President and Chief Financial Officer. During the QA session, …
  • of
  • the non-GAP measures used in this release. The release, as well as reconciliations of the …
  • divestitures for which there is less than a full period of comparable net sales. Guidance …
  • website. On this call, all references to sales and revenue are organic and relative growth…
  • beliefs using information available to us as of today's date and not intended to be guaran…
  • are discussed in the earnings release we issued earlier this morning and our periodic repo…
  • addition, this call does not constitute an offer to sell or the solicitation of an offer t…
  • of
  • any vote or approval in connection with the proposed transaction with Penumbra. Boston Sci…
  • about
  • Penumbra, Boston Scientific, the proposed transaction, and related matters. At this point,…

Speaker 2

Unverified voice label

Thanks, Lauren. Thank you everyone for joining us today. I want to begin by walking through our third-quarter results, provide some fourth quarter outlook, and then assumptions behind our updated view of 2027. I'll then provide more details on both the region and business unit performance and outlook. Q3 total company organic sales grew 1.5% versus a guide, first original guide of 3% to 5%.

Q3 adjusted EPS of 73%, 73 cents declined 3% versus our guidance range of 80 to 82. Our Q3 results were impacted by our previously reported cybersecurity incident, which we estimate reduced our sales growth by approximately 300
basis points and adjusted EPS by 7 cents in the quarter. Importantly, after a two-week outage as a result of the cyber incident, all operations are back up and running as of September 8th.

I'm very proud of our team's resiliency
?and the efforts they made to help us return as quickly as possible to supporting physicians and their patients for their products. Turning to Q4, ?we anticipate that it will be at 200 to 300 basis points of impact from the cyber incident ?as we work through elevated customer orders at the end of Q3 to replenish inventory levels.

Additionally, since our second quarter second quarter earnings call, EP share pressure has intensified, further accelerated by the cyber incident. We have also seen pricing dynamics in China become more challenging.
?To that end, we are guiding to organic revenue declines of minus one to minus three percent for the fourth quarter of 26 and adjusted EPS of 77 cents to 79 cents. This results in a full-year 26 organic revenue growth guide of approximately 4% and EPS of 316 to 318.

Boston
Scientific has enjoyed several years of exceptional growth, driven by strategic investments and strong execution globally, particularly within our EP and Watchman franchises. In 26, we've seen that cycle turn, and those two businesses are now weighing on our total company growth as we navigate competition and market dynamics. ?We believe that 2027 will be the trough in the cycle, and we have several investments and new innovations coming over the course of the next three years that we expect will support stabilization and growth for both the EP and Watchman businesses. ?

And
while the remaining 75% of our business has grown consistently, we anticipate there will be additional price headwinds in China in 27, ?and the growth likely won't be enough to offset the pressure from EP and watchmen next year. As a result, we believe we'll be challenged to grow sales and adjusted EPS in 27, excluding our pending acquisition of Penumbra. Having said all that, we are taking immediate actions to prepare for the future, including through our previously announced restructuring program and the evolution of our operating structure, while ensuring that we continue to make the right strategic investments across a number of growth platforms. ?

We
have a very strong cadence of launches in 27 and 28 and anticipate endings entering several new markets over the next few years ?that will unlock $25 billion in new market opportunity by 2030. Importantly, we expect these actions to drive meaningful improvement in both our revenue and adjusted EPS performance ?as we aim to exit this cycle in 27 ?and return to delivering high performance in 28 with further improvement expected in 29.

I'll now provide some more details on Q3 in full year 26. Turning to our regional performance, the US was flat year over year on an operational basis driven by ICBT, IONE, and neuromodulation. Europe, Middle East, and
Africa grew 6% on an operational basis with strong performance across many of our businesses. But within the quarter, there was some impact from cyber, offset by a transient headwind in third quarter 25 from our ERP platform GoLive.

Asia Pat Asia Pacific declined 1% operationally with growth impacted by the cyber incident,
as well as price pressure in China. Pricing dynamics in China continue to evolve, and the number of our businesses seeing VBP and other pricing impacts as a result. We expect growth in this market will moderate to single digit growth. Turning to our business units, I'll start with neuromodulation. Sales growth 13%.

In pain
growth was broad based across the portfolio with exceptional performance with our Nalu PS technology. But within the quarter, data was presented from the improved study evaluating our intracept technology with real-world outcomes showing improvements in pain function and quality of life at three months. ?In brain, growth was driven by our Categor X lead and Alumina 3D software, which enabled more precise placement and programming.

Urology declined 3% this quarter with impact from the cyber incident as well as expanding pricing pressure in China. In stone management, we have received a number of approvals for key products, including F-Day clearance
of our Navigator Flex suction seat, CEMARC and FDA clearance for distribution of the 7.5 Slim Scope ?and FDA clearance of our Lithu Elite Single Use Eretroscope. ?As we look forward, we expect these new stone launches as well as stabilization and productivity from our SNM commercial organization to help our urology performance improve its growth profile over the course of 2027.

Endoscopy sales declined 1% versus Q325, inclusive of an impact from China BVP and
cyber. Importantly, the underlying performance of this business continues to be strong, led by Axios, our differentiated technology. ?And as we look ahead, we expect our endoscopy performance to be slightly pressured, closer to mid-single-digit market growth, until we annualize the impact from the China VVP in the fourth quarter 27.

Cardiovascular sales delivered growth at 2%,
?and interventional cardiology and vascular therapies sales grew 12%. ?Our interventional cardiology business had another exceptional quarter, growing 19%, with continued strength in our global imaging franchise and drug loading technologies. ?We had another outstanding quarter of our agent DCB, which is backed by strong clinical evidence, ?and now it's been used to treat over 400,000 patients to ?date.

We
remain focused on both the near and longer-term growth opportunities for this business. And last quarter, we received ID approval of the vital PCI trial ?that is studying our vitalist circulatory support technology in the high-risk PCI population. However, considering evolving clinical evidence in the space, we've made a decision to shift our strategy ?and focus our development clinical efforts on the AMI cardiogenic shock indication. ?

We
believe that our device design has the potential to be well suited to treat patients experiencing cardiogenic shock and look forward to initiating clinical efforts in 27. ?Our Vitalous program is one of the largest internal RD programs and an important long-term growth driver. To solidify funding for the AMI shock program, we have entered an agreement with Blackstone Life Sciences and aim to bring this important technology to market in 2030. ?

Our
vascular therapies business grew 1% with some impact from cyber ?as well as T car supply constraints. Importantly, we anticipate that our T car supply to improve throughout the fourth quarter with full resolution by early next year. ?Our seismic launch continues to go well, and within the quarter, we received FDA clearance for seismic IVL, sorry, seismic IVL to treat patients with severely calcified peripheral artery disease in small vessel, expanding our seismic matrix to now treat above the knee and below the knee.

We also received FDA approval for the
Ranger 035 drug-coded balloon, offering an expanded size and providing a highly complimentary offering as most IVL procedures that are performed in lower limbs are also followed by drug eluding technologies. ?We remain excited about the opportunity to add penumber to add the penumber team ?and they're highly differentiated in the complementary portfolio to Boston Scientific. We continue to work with regulators and now expect to close in early 27, subject to the receipt of the remaining regulatory clearances. ?

Our
interventional oncology and embolization business grew 5%, driven by strong performance in our cancer therapies franchise, partially offset by some supply constraints ?that we anticipate will be resolved in early 2027. We continue to see strong adoption of any day dosing on Therosphere 360, as well as momentum with our hepatic artery infusion technology, providing a portfolio of options for cancer treatment. Cardiac rhythm management sales declined minus 2% with some impact from the cyber incident as we navigated usage and activation of technologies that leverage remote monitoring while our systems were down.

In Q3, our diagnostics franchise grew high single digits,
?our low voltage business declined mid single digits, ?and high voltage business declined low single digits. We anticipate that our performance will improve over the course of 27 with new launches and ongoing momentum. Before I turn to Watchman and EP, I want to acknowledge the pressures in these two businesses and the impact that it has on our overall growth. ?

We
are acting now to strengthen the LAC market and focus our EP resources where we can compete most effectively, while investing in innovation that we believe can improve over time. ?On Watchmen, sales declined minus 6%, declining 7% in the US, ?and growing 4% internationally. Within the U.S., concomitant procedures grew approximately 35%, and standalone procedures declined high teens versus third quarter 25. We continue to believe that the overall LEC market slowdown primarily reflects changes in patient identification and referral patterns as physicians assess the clinical evidence published over the last year.

Importantly, we are executing against our investment priorities that we laid out in our two call. We held over 200 Med events in the second quarter and third quarter, providing an opportunity for more than 2,000 referrals and implanters to gain a deeper understanding of
the clinical evidence available. We've added more dedicated commercial resources to watchmen to support both concomitant and standalone procedures and support the referral pathway. ?

In
a third quarter, we saw increased patient engagement, further reinforcing the strong demand for alternatives to oral anticoagulation ?and highlighting the significant unmet need of my patients who can't, shouldn't, or won't take lifelong OAC. We continue to believe that focusing on these priorities will support improvement in the LAC market over time. With a third quarter performance largely in line with expectations despite the cyber incident, we are maintaining our previous outlook for our watchman business. ?

In
fourth quarter, within the U.S., we anticipate no improvement ?in the year-over-year standalone procedure performance and continued deceleration and concomitant procedure growth against a very high baseline. Internationally we anticipate similar performance in Q3 and Q4, resulting in sequential flat, low single-digit declines versus Q326 globally. Turning to 27, we believe our investments, along with a potential label change, will improve the market over time.

However, until we see the market improve, we are assuming that the market performance will be similar to Q4 with additional pressure due to a new competitive launch.
?We believe in the benefit of this therapy and continue to innovate and invest for the future. Within the quarter, we commence enrollment in the elite AF clinical trial to evaluate the safety and effectiveness of the next generation Watchman Elite platform. ?

We
anticipate bringing this fourth generation technology to market in 29. ?And additionally, we look forward to the late breaking data presentation of our Simplify trial at TCT, studying post-implant drug therapy using Watchman Flex Pro ?and assessing whether a less intensive drug regimen may help mitigate post-implant bleeding risk. Turning to EP, sales declined 5% with a decline with a decline of 8% in the US and 2% growth internationally. ?

We
estimate that the cyber incident contributed to roughly half our MIST, primarily within our international region. But within the quarter, we continue to expand our Opal footprint and drive more utilization of our mapping systems ?with our Fairrowave and FairPoint catheters. ?The EP market has transformed over the past few years, led by our differentiated Ferropuls platform. ?We have seen our strong market share position erode as new technologies are introduced, and adoption of these different PFA form factors has been highly dynamic.

While the cyber incident has accelerated some of the share shift, we do expect continued erosion of our PFA share position until we launch Farrowwave Ultra, now expected in early
28. We expect our EP performance to meaningfully improve in 28 as we expand our PFA ecosystem with 2D ice in the second half of 27 ?and ferrowave Ultra in 28 ?and Ferroflex, a wide area focal catheter in 29. ?

In
the near term, we're focusing our teams where we know we can win. ?We have the most utilized and studied technology for de novo AFI vation procedures ?with our Ferrowwave catheters. ?We have a differential portfolio available, including our VersaCross transseptal needle and watchman technology, and we continue to invest to bring differentiated innovation to this large and fast growing ?market. In closing, I want to restate that I remain very confident in Boston Scientific's long term long long-term outlook.

We operate in attractive markets with approximately 75% of our business, historically growing approximately 66% for many quarters.
?We have an impactful cadence of future growth catalysts anticipated in 27 and 28, that we expect to drive meaningful improvement to our growth profile in 28 and beyond. We remain focused on execution, delivering our updated 26 guidance, taking appropriate action to evolve our organization that will create greater focus, speed, and accountability, while ensuring we are continuing to invest in our long term growth drivers. ?

I'm
incredibly grateful to our global employees for their resiliency and winning spirit. And across all of our businesses and regions, I've seen our colleagues step up in extraordinary ways, adapting quickly and supporting one another and doing what it takes to ensure we are focused on what matters, improving patient lives through a relentless, relentless pursuit of innovation. ?With that in hand, I'll hand over to John to provide more details.

Passages & reports (136)
  • Thanks, Lauren. Thank you everyone for joining us today. I want to begin by walking throug…
  • versus a guide, first original guide of 3% to 5%. Q3 adjusted EPS of 73%, 73 cents decline…
  • basis points and adjusted EPS by 7 cents in the quarter. Importantly, after a two-week out…
  • and
  • the efforts they made to help us return as quickly as possible to supporting physicians an…
  • we
  • anticipate that it will be at 200 to 300 basis points of impact from the cyber incident
  • as
  • we work through elevated customer orders at the end of Q3 to replenish inventory levels. A…
  • To
  • that end, we are guiding to organic revenue declines of minus one to minus three percent f…
  • Scientific has enjoyed several years of exceptional growth, driven by strategic investment…
  • We
  • believe that 2027 will be the trough in the cycle, and we have several investments and new…
  • And
  • while the remaining 75% of our business has grown consistently, we anticipate there will b…
  • and
  • the growth likely won't be enough to offset the pressure from EP and watchmen next year. A…
  • previously announced restructuring program and the evolution of our operating structure, w…
  • We
  • have a very strong cadence of launches in 27 and 28 and anticipate endings entering severa…
  • that
  • will unlock $25 billion in new market opportunity by 2030. Importantly, we expect these ac…
  • as
  • we aim to exit this cycle in 27
  • and
  • return to delivering high performance in 28 with further improvement expected in 29. I'll …
  • Africa grew 6% on an operational basis with strong performance across many of our business…
  • as well as price pressure in China. Pricing dynamics in China continue to evolve, and the …
  • growth was broad based across the portfolio with exceptional performance with our Nalu PS …
  • In
  • brain, growth was driven by our Categor X lead and Alumina 3D software, which enabled more…
  • of our Navigator Flex suction seat, CEMARC and FDA clearance for distribution of the 7.5 S…
  • and
  • FDA clearance of our Lithu Elite Single Use Eretroscope.
  • As
  • we look forward, we expect these new stone launches as well as stabilization and productiv…
  • cyber. Importantly, the underlying performance of this business continues to be strong, le…
  • And
  • as we look ahead, we expect our endoscopy performance to be slightly pressured, closer to …
  • and
  • interventional cardiology and vascular therapies sales grew 12%.
  • Our
  • interventional cardiology business had another exceptional quarter, growing 19%, with cont…
  • We
  • had another outstanding quarter of our agent DCB, which is backed by strong clinical evide…
  • and
  • now it's been used to treat over 400,000 patients to
  • date. We
  • remain focused on both the near and longer-term growth opportunities for this business. An…
  • that
  • is studying our vitalist circulatory support technology in the high-risk PCI population. H…
  • and
  • focus our development clinical efforts on the AMI cardiogenic shock indication.
  • We
  • believe that our device design has the potential to be well suited to treat patients exper…
  • Our
  • Vitalous program is one of the largest internal RD programs and an important long-term gro…
  • Our
  • vascular therapies business grew 1% with some impact from cyber
  • as
  • well as T car supply constraints. Importantly, we anticipate that our T car supply to impr…
  • Our
  • seismic launch continues to go well, and within the quarter, we received FDA clearance for…
  • Ranger 035 drug-coded balloon, offering an expanded size and providing a highly compliment…
  • We
  • remain excited about the opportunity to add penumber
  • to add the penumber team
  • and
  • they're highly differentiated in the complementary portfolio to Boston Scientific. We cont…
  • Our
  • interventional oncology and embolization business grew 5%, driven by strong performance in…
  • that
  • we anticipate will be resolved in early 2027. We continue to see strong adoption of any da…
  • impact from the cyber incident as we navigated usage and activation of technologies that l…
  • our
  • low voltage business declined mid single digits,
  • and
  • high voltage business declined low single digits. We anticipate that our performance will …
  • We
  • are acting now to strengthen the LAC market and focus our EP resources where we can compet…
  • On
  • Watchmen, sales declined minus 6%, declining 7% in the US,
  • and
  • growing 4% internationally. Within the U.S., concomitant procedures grew approximately 35%…
  • physicians assess the clinical evidence published over the last year. Importantly, we are …
  • the clinical evidence available. We've added more dedicated commercial resources to watchm…
  • In
  • a third quarter, we saw increased patient engagement, further reinforcing the strong deman…
  • and
  • highlighting the significant unmet need of my patients who can't, shouldn't, or won't take…
  • our watchman business.
  • In
  • fourth quarter, within the U.S., we anticipate no improvement
  • in
  • the year-over-year standalone procedure performance and continued deceleration and concomi…
  • 27, we believe our investments, along with a potential label change, will improve the mark…
  • We
  • believe in the benefit of this therapy and continue to innovate and invest for the future.…
  • We
  • anticipate bringing this fourth generation technology to market in 29.
  • And
  • additionally, we look forward to the late breaking data presentation of our Simplify trial…
  • and
  • assessing whether a less intensive drug regimen may help mitigate post-implant bleeding ri…
  • We
  • estimate that the cyber incident contributed to roughly half our MIST, primarily within ou…
  • with
  • our Fairrowave and FairPoint catheters.
  • The
  • EP market has transformed over the past few years, led by our differentiated Ferropuls pla…
  • We
  • have seen our strong market share position erode as new technologies are introduced, and a…
  • 28. We expect our EP performance to meaningfully improve in 28 as we expand our PFA ecosys…
  • and
  • ferrowave Ultra in 28
  • and
  • Ferroflex, a wide area focal catheter in 29.
  • In
  • the near term, we're focusing our teams where we know we can win.
  • We
  • have the most utilized and studied technology for de novo AFI vation procedures
  • with
  • our Ferrowwave catheters.
  • We
  • have a differential portfolio available, including our VersaCross transseptal needle and w…
  • market. In
  • closing, I want to restate that I remain very confident in Boston Scientific's long term l…
  • We
  • have an impactful cadence of future growth catalysts anticipated in 27 and 28, that we exp…
  • ensuring we are continuing to invest in our long term growth drivers.
  • I'm
  • incredibly grateful to our global employees for their resiliency and winning spirit. And a…
  • pursuit of innovation.
  • With
  • that in hand, I'll hand over to John to provide more details.

Speaker 1

Thanks, Mike.

Passages & reports (1)
  • Thanks, Mike.

third quarter financial performance,

Passages & reports (1)
  • third quarter financial performance,

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 2

want ?to express my gratitude to our customers, physicians, and employees for their patience and partnership ?as we work through the recent cyber incident. ?I'm very proud of our global teams who have worked diligently to restore operations and continue to support our customers ?and the patients that they serve. ?The cyber incident caused significant disruption to our business operations, ?and it materially impacted our third quarter financial results.

Despite these challenges, we remain focused on taking
?the necessary actions to drive improved financial performance. ?So turning now to the quarter, third quarter consolidated revenue of $5,138,000,000 represents 1.5% reported growth versus third quarter 2025 and includes a neutral impact from foreign exchange, which was in line with expectations. As a result, operational ?and organic revenue growth were also

Passages & reports (19)
  • want
  • to
  • express my gratitude to our customers, physicians, and employees for their patience and pa…
  • as
  • we work through the recent cyber incident.
  • I'm
  • very proud of our global teams who have worked diligently to restore operations and contin…
  • and
  • the patients that they serve.
  • The
  • cyber incident caused significant disruption to our business operations,
  • and
  • it materially impacted our third quarter financial results. Despite these challenges, we r…
  • the
  • necessary actions to drive improved financial performance.
  • So
  • turning now to the quarter, third quarter consolidated revenue of $5,138,000,000 represent…
  • and organic revenue
  • growth were also

Speaker unclear

?1.5% in the quarter, below our third quarter

Passages & reports (1)
  • 1.5% in the quarter, below our third quarter

Speaker 2

guidance range of 3% to 5%. We estimate the cyber

Passages & reports (1)
  • guidance range of 3% to 5%. We estimate the cyber

Speaker unclear

?incident had a net negative impact

Passages & reports (1)
  • incident had a net negative impact

Speaker 2

of ?approximately 300 basis points on third quarter organic revenue growth. This impact reflects the eight business day disruption to our global network, during which we ?are unable to manufacture or ship product, partially offset by revenue recovered

Passages & reports (5)
  • of
  • approximately 300 basis
  • points on third quarter organic revenue growth. This impact reflects the eight business da…
  • are unable to
  • manufacture or ship product, partially offset by revenue recovered

Speaker 3

Unverified voice label

as ?operations resumed. Third quarter 2026 adjusted earnings per share of 73 cents declined 3% versus 2025, below our third quarter guidance range of 80 to 82 cents. As Mike mentioned, third quarter results include an approximate seven cent unfavorable impact from the cyber incident, primarily driven by lower than expected sales and the additional manufacturing and operating costs associated with the cyber incident. Adjusted gross margin for the third quarter was 68.0%, representing a 300 basis point decrease versus the third quarter of 2025, primarily driven by unfavorable manufacturing absorption during the cyber related disruption.

Third quarter adjusted operating margin was 26.5%, contracting 150 basis points versus the third quarter of 2025, primarily driven by the impact
?of the cyber incident on gross margin. ?On a gap basis, third quarter operating margin was 16.1%. These results include an approximate $80 million charge primarily related to certain product liability cases. Moving to below the line, third quarter adjusted interest and other expenses totaled $124 million, which was in line with expectations.

On an adjusted basis,
?our tax rate for the third quarter was 14.3%, which was higher than expected due to certain discrete tax items. Fully diluted weighted average shares outstanding ended at $1,452 million in the third quarter, ?and free cash flow for the third quarter was $867 million with $1,047 million from operating activities, less $180 million, in net capital expenditures. ?As of September 30th, 2026, ?we had cash on hand of $609 million, and our gross debt leverage ratio was $1.9 times. ?

Our
capital allocation approach remains disciplined and growth oriented. Our top priorities remain strategic Tuck and MA and opportunistic share repurchases, while we continue to evaluate and fund the opportunities that we believe will create the greatest long term value for our shareholders. ?We look forward to closing our acquisition of Penumbra, which we believe will strengthen our long term growth profile through its innovative portfolio and strong strategic fit within our cardiovascular business. ?

In
addition to Tuck and MA, we're leveraging strategic partnerships to advance innovation, ensuring we're directing capital toward high growth opportunities. Consistent with this approach, we recently entered into an agreement with Blackstone Life Sciences to co-fund the development of our vitalist circulatory support system ?for the treatment of patients with cardiogenic shock. Under the agreement, Boston Scientific will receive funding from Blackstone, which will be recognized as a reduction to RD expense as the related costs are incurred.

Upon achievement of certain milestones expected starting in 2030, Blackstone will be eligible to receive a return on the actual
amount funded for the program, plus royalties on sales of Vitalist. This agreement allows us to continue advancing Vitalist while accelerating investments in other high growth opportunities. Before I discuss guidance, ?I want to acknowledge that we need to rebuild confidence in our forecasts. We've implemented meaningful enhancements to our forecasting process, which we believe provide a stronger foundation for more accurate forecasting going forward. ?

And
so now I'll walk through our guidance for the fourth quarter and full year 2026. We now expect full year 2026 reported revenue growth to be approximately 4.25% versus 2025, excluding an approximate 50 basis point tailwind from foreign exchange based on current rates. We expect full year 2026 operational and organic growth to be approximately 3.75%.

Passages & reports (32)
  • as
  • operations
  • resumed. Third quarter 2026 adjusted earnings per share of 73 cents declined 3% versus 202…
  • primarily driven by lower than expected sales and the additional manufacturing and operati…
  • driven by unfavorable manufacturing absorption during the cyber related disruption. Third …
  • of
  • the cyber incident on gross margin.
  • On
  • a gap basis, third quarter operating margin was 16.1%. These results include an approximat…
  • which was in line with expectations. On an adjusted basis,
  • our
  • tax rate for the third quarter was 14.3%, which was higher than expected due to certain di…
  • and
  • free cash flow for the third quarter was $867 million with $1,047 million from operating a…
  • As
  • of September 30th, 2026,
  • we
  • had cash on hand of $609 million, and our gross debt leverage ratio was $1.9 times.
  • Our
  • capital allocation approach remains disciplined and growth oriented. Our top priorities re…
  • We
  • look forward to closing our acquisition of Penumbra, which we believe will strengthen our …
  • In
  • addition to Tuck and MA, we're leveraging strategic partnerships to advance innovation, en…
  • for
  • the treatment of patients with cardiogenic shock. Under the agreement, Boston Scientific w…
  • amount funded for the program, plus royalties on sales of Vitalist. This agreement allows …
  • I
  • want to acknowledge that we need to rebuild confidence in our forecasts. We've implemented…
  • And
  • so now I'll walk through our guidance for the fourth quarter and full year 2026. We now ex…
  • 2026 operational and organic growth to be approximately 3.75%.

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 3

expect fourth quarter 2026 reported revenue to decline in a range of down 3% to down 1% versus fourth quarter 2025. ?We anticipate no impact from foreign exchange based on current rates and therefore expect fourth quarter 2026 operational and organic revenue to also decline in a range of down 3% to down 1%.

Passages & reports (3)
  • expect fourth quarter 2026 reported revenue to decline in a range of down 3% to down 1% ve…
  • We
  • anticipate no impact from foreign exchange based on current rates and therefore expect fou…

Speaker unclear

?As

Passages & reports (1)
  • As

Speaker 3

Mike mentioned, our fourth quarter guidance contemplates a headwind from the cyber incident, reflecting elevated customer ordering at the end of the third quarter, which we expect to normalize over the course of the fourth quarter.

Passages & reports (1)
  • Mike mentioned, our fourth quarter guidance contemplates a headwind from the cyber inciden…

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 3

expect full year 2026 adjusted gross margin to be below full year 2025, reflecting a less favorable product mix, investment in our global supply chain and quality systems, ?and the additional impact of the cyber incident. ?We now expect full year 2026 adjusted operating margin to be approximately 27.6%, reflective of gross margin pressures. We continue to expect full year 2026 adjusted below the line expense to be approximately $485 million.

Under current legislation, including enacted
laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximately 12%. ?We expect full year 2026 free cash flow to be approximately $3.6 billion, reflecting a reduced operating income outlook. ?We expect full year 2026 adjusted earnings per share to be in a range of $3.16 to $3.18, representing growth of 3% to 4% versus 2025, including an approximate six cent headwind from foreign exchange.

We expect fourth quarter adjusted
earnings per share to be in a range of 77 cents to 79 cents.

Passages & reports (11)
  • expect full year 2026 adjusted gross margin to be below full year 2025, reflecting a less …
  • and
  • the additional impact of the cyber incident.
  • We
  • now expect full year 2026 adjusted operating margin to be approximately 27.6%, reflective …
  • laws and issued guidance, we now expect a full year 2026 adjusted tax rate of approximatel…
  • We
  • expect full year 2026 free cash flow to be approximately $3.6 billion, reflecting a reduce…
  • We
  • expect full year 2026 adjusted earnings per share to be in a range of $3.16 to $3.18, repr…
  • earnings per share to be in a range of 77 cents to 79 cents.

Speaker unclear

?As

Passages & reports (1)
  • As

Speaker 3

Mike outlined, we anticipate continued top top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earnings per share, excluding Penumbra. We expect our underlying business dynamics in Q4 to persist into 2027, ?and believe our fourth quarter guidance provides a reasonable baseline for next year's revenue ?and adjusted earnings per share outlook. Importantly, we're taking decisive actions to drive greater focus, speed, and accountability, ?most most notably through our company-wide restructuring program.

This comprehensive initiative is focused on org structure evolution, supply chain optimization, back office transformation, and reductions in other categories of spend.
?We expect these efforts to deliver sustained cost efficiencies while allowing us to prioritize investments that support long-term growth. In closing, ?we believe we're well positioned in attractive markets, we're making the right investments, and taking the necessary steps to strengthen our financial performance.

I'm confident that these actions will position us to stabilize Boston Scientific in 2027
?and then drive improved revenue and adjusted earnings per share growth in 2028, ?and then further acceleration in 2029. For more information, please check our investor relations website for third quarter 2026 financial and operational highlights, which outlines more details on third quarter results and 2026 guidance. ?And so Lauren with that, uh ?I'll turn it back to you to moderate the QA.

Passages & reports (19)
  • Mike outlined, we anticipate continued top top-line pressure into 2027, which we expect wi…
  • and
  • believe our fourth quarter guidance provides a reasonable baseline for next year's revenue
  • and
  • adjusted earnings per share outlook. Importantly, we're taking decisive actions to drive g…
  • most
  • most notably through our company-wide restructuring program. This comprehensive initiative…
  • We
  • expect these efforts to deliver sustained cost efficiencies while allowing us to prioritiz…
  • we
  • believe we're well positioned in attractive markets, we're making the right investments, a…
  • and
  • then drive improved revenue and adjusted earnings per share growth in 2028,
  • and
  • then further acceleration in 2029. For more information, please check our investor relatio…
  • And
  • so Lauren with that, uh
  • I'll
  • turn it back to you to moderate the QA.

Speaker 1

Thanks, John. True, let's open it up for questions for the next 30 minutes or so. In order for us to take as many questions as possible, please limit yourself to one question. True, please go ahead.

Passages & reports (1)
  • Thanks, John. True, let's open it up for questions for the next 30 minutes or so. In order…

Speaker 0

Thank you. We will now begin the question and answer session. To ask a question, you may press star than one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you'd like to withdraw your question, please press star then two. Again, please limit yourself to only one question.

At this time we will pause momentarily to assemble our roster. The first question comes from Robbie Marcus with JP Morgan. Please go ahead.

Passages & reports (2)
  • Thank you. We will now begin the question and answer session. To ask a question, you may p…
  • please press star then two. Again, please limit yourself to only one question. At this tim…

Questions & answers

Speaker 4

Unverified voice label

A lot to dig into. I'll I'll stick with one here and and focus on guidance?

Passages & reports (1)
  • A lot to dig into. I'll I'll stick with one here and and focus on guidance?

Maybe you could, and and there's a lot of questions I'm getting from investors, so hopefully this will help clarify. How do we think about sort of the actual underlying impact from the hack disruption in third quarter? ?It sounds like there was some order benefits. What's the actual impact and why bleeding into fourth quarter? And with the no growth comment on twenty seven, how much of that is conservatism related to the hack and how much is new information of and market and uh product timing?

Thanks a

Passages & reports (4)
  • Maybe you could, and and there's a lot of questions I'm getting from investors, so hopeful…
  • It
  • sounds like there was some order benefits. What's the actual impact and why bleeding into …
  • market and uh product timing? Thanks a

Speaker unclear

?lot. John,

Passages & reports (1)
  • lot. John,

Speaker 2

you want to take the cyber question?

Passages & reports (1)
  • you want to take the cyber question?

Speaker 3

Sure. Yeah, thanks, uh Robbie. So let me lay out the impacts of cyber. So in Q3, uh we estimate a roughly 300 basis point headwind ?uh to our revenue from cyber. So call it roughly 150 million dollars of headwind on the top line, ?and then bottom line impact to EPS of seven cents. So at the impact of the lost sales, we did have uh unfavorable manufacturing absorption that contributed to uh the seven cents of EPS, ?uh, as well as um other direct costs, expedited shipping, uh, cost of experts uh that impacted Q3 cyber.

For the fourth quarter, we expect an ongoing impact of approximately 200 to 300 uh basis points. Um, and so
?what we saw, Robbie, coming out of the cyber incident is um a level of stocking of ?uh from customers, and over the third fourth quarter will burn off um some of those inventory levels. So that's why you see the ongoing impact into the fourth quarter ?of that 200 to 300 bips, ?and then that drops through down to EPS uh roughly four to five cents of impact in the fourth

Passages & reports (15)
  • Sure. Yeah, thanks, uh Robbie. So let me lay out the impacts of cyber. So in Q3, uh we est…
  • uh
  • to our revenue from cyber. So call it roughly 150 million dollars of headwind on the top l…
  • and
  • then bottom line impact to EPS of seven cents. So at the impact of the lost sales, we did …
  • uh,
  • as well as um other direct costs, expedited shipping, uh, cost of experts uh that impacted…
  • what
  • we saw, Robbie, coming out of the cyber incident is um a level of stocking of
  • uh
  • from customers, and over the third fourth quarter will burn off um some of those inventory…
  • of
  • that 200 to 300 bips,
  • and
  • then that drops through down to EPS uh roughly four to five cents of impact in the fourth

Speaker unclear

?quarter.

Passages & reports (1)
  • quarter.

Speaker 2

Yeah, maybe just some comments on uh the question. ?You know, when we think about it, we obviously uh aim to uh exceed these uh expectations, but just to frame it, we'll give our guidance obviously

Passages & reports (3)
  • Yeah, maybe just some comments on uh the question.
  • You know,
  • when we think about it, we obviously uh aim to uh exceed these uh expectations, but just t…

Speaker 3

in January.

Passages & reports (1)
  • in January.

Speaker unclear

?Uh

Passages & reports (1)
  • Uh

Speaker 2

we

Passages & reports (1)
  • we

Speaker 3

really do expect some of the underlying

Passages & reports (1)
  • really do expect some of the underlying

Speaker 2

business

Passages & reports (1)
  • business

Speaker 3

dynamics

Passages & reports (1)
  • dynamics

Speaker 2

that we see in the fourth quarter to persist in 2027. ?So if you look at that, you've got a number of our businesses doing extremely well, interventional cardiology, vascular, Io and E, ?uh endoscopy's uh underlying

Passages & reports (5)
  • that we see in the fourth quarter to persist in 2027.
  • So
  • if you look at that, you've got a number of our businesses doing extremely well, intervent…
  • uh
  • endoscopy's uh underlying

Speaker 3

business ?uh is doing quite well despite the

Passages & reports (3)
  • business
  • uh
  • is doing quite well despite the

Speaker 2

pressures

Passages & reports (1)
  • pressures

Speaker 3

in

Passages & reports (1)
  • in

Speaker 2

uh

Passages & reports (1)
  • uh

Speaker 3

in

Passages & reports (1)
  • in

Speaker 2

China. So the

Passages & reports (1)
  • China. So the

Speaker 3

overall

Passages & reports (1)
  • overall

Speaker 2

base business we feel is consistently growing about 6%. We expect about uh a point of impact due to the comprehensive China uh pricing issues, and that represents about 75% of the business. So the two key areas questions are what will be the impact of watchmen and EP in 2027? So for the basis of our uh early framing of guidance, we wanted to be appropriately conservative.

So we're assuming that the watchmen market dynamics do not improve over current state. And we ex uh we're obviously doing a lot to turn that around.
?But those underlying markets today are growing about negative seven, negative eight ish uh percent in that area. And we do have a competitive launch coming in 2027. So the error bars around the market, uh around the watchman assumptions are quite wide, given that we are assuming no improvement uh in the market, despite some of our efforts and an anticipated label change, where we're assuming that the market baseline stays similar to Q4 with competitive entry in 27.

Similarly in EP, EP will be a challenging year for us in 27, and we're very optimistic about 28 and 29 based on our product launch cadence. But in
27, we are lacking new product launches. The market continues to be fairly healthy, but we expect to continue to seed share in 2027 in EP,

Passages & reports (6)
  • base business we feel is consistently growing about 6%. We expect about uh a point of impa…
  • of our uh early framing of guidance, we wanted to be appropriately conservative. So we're …
  • But
  • those underlying markets today are growing about negative seven, negative eight ish uh per…
  • of our efforts and an anticipated label change, where we're assuming that the market basel…
  • 27, we are lacking new product launches. The market continues to be fairly healthy, but we…

Speaker 3

similar to the

Passages & reports (1)
  • similar to the

Speaker 2

rates that we've seen in the second half

Passages & reports (1)
  • rates that we've seen in the second half

Speaker 3

of

Passages & reports (1)
  • of

Speaker 2

2026 until we successfully launch a lot a ICE program ?in second half of 27. ?Uh an excellent platform upgrade with FerroPulse Ultra, ?uh ideally late fourth quarter, early first quarter 27. And as you know, we're we've initiated our uh clinical trial of our Ferriflex platform, which will be an early 29 launch. ?So hopefully that gives you some context for 2027.

Passages & reports (9)
  • 2026 until we successfully launch a lot a ICE program
  • in
  • second half of 27.
  • Uh
  • an excellent platform upgrade with FerroPulse Ultra,
  • uh
  • ideally late fourth quarter, early first quarter 27. And as you know, we're we've initiate…
  • So
  • hopefully that gives you some context for 2027.

Speaker 0

Thank you. The next question comes from Larry Beagleson with Wells Fargo. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Larry Beagleson with Wells Fargo. Please go ahead.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 5

Unverified voice label

guys, thanks for taking the question. So it was super helpful, you know, color on on uh 2026 and 2027. Mike, just talk about your confidence in improving sales and EPS growth in 28. Um I'm not looking for specifics, obviously, but what are what are the drivers? ?You know, it looks like Farraflex, the launch was pushed out to 2029 in the slides if I'm reading that correctly.

And
?you know, I think there are some concerns about new PFA competition coming in 28 uh with a novel waveform. And so how are you factoring that in? Thank

Passages & reports (5)
  • guys, thanks for taking the question. So it was super helpful, you know, color on on uh 20…
  • You
  • know, it looks like Farraflex, the launch was pushed out to 2029 in the slides if I'm read…
  • you
  • know, I think there are some concerns about new PFA competition coming in 28 uh with a nov…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yeah, thank you. Yeah, just a backdrop a bit and maybe not new news. Uh 23 to 25, we experienced a very high growth cycle, uh much on the heels of our base business being strong and the tremendous growth of uh watchman and EP. We also had a decent first half uh despite some of our forecasting challenges growing 8% in the first half of 2026.

We are clearly in the middle of a down cycle, which is a short-term phenomenon for Boston Scientific, that you will see that we predicted in the fourth quarter based on our guide in 2027. We are very confident about the return to
growth and kind of pushing off the bottom in 27 as we enter 28. And the high level formula for growth in 28, ?you know, potentially below our WAMGAR, but solid growth, and growth above our Whamger in 29, really are the, if you look at our three segments, ?our biggest segment as you look at 2028 will be our interventional cardiology, vascular, and penumbra business.

We expect that collection of businesses to comfortably grow above their market Whamger
?as Penumbra goes organic and they continue to derive excellent momentum. ?And with a very strong portfolio cadence in that business, with our IVL platforms and peripheral and vascular, potentially hypertension in 2028, ?and a strong cadence of imaging capabilities as well as launches within our VT IOE platform. So that will represent our biggest segment, very much on offense, growing above Whamgur and propelling the growth of the company.

Our med surge business with a number of key launches, you saw a couple key approvals just
this quarter in our geology business. ?We expect our med surge segment businesses to essentially grow at our market whamger or grow at their market whamger, call it mid single digits. So then it really comes down to what happens to EP and Watchmen and CRM. The good news in CRM is we'll be launching a significant platform launch with Denali, our defibrillator platform, which we expect uh CRM will comfortably return to growth in 2028 to help that segment. ?

And
then in Watchmen, we will anniversary a competitive launch in 2028. We'll be in the midst of a trial of our fourth generation platform. As you know, we've got very, very strong share in Watchmen, and we expect to maintain that strong leadership position during this case. We'll also aim to have a approved label change ideally by 2028. So we see the watchman business kind of maximum down is in 2027 and will return to a healthier uh position in 2028.

Similar with our EP business, again, it's driven by portfolio and cadence. And as I mentioned before, we'll have our ICE platform
launch, our full full year of Ferapulse Ultra, and pending approval or flex uh business. So we expect the overall uh rhythm solutions business with a stronger growth in CRM and improving cadence of effective launches in EP and uh watchmen to significantly improve the growth profile of rhythm in 28, whereas 2027, that segment's driving uh the challenges.

Passages & reports (22)
  • Yeah, thank you. Yeah, just a backdrop a bit and maybe not new news. Uh 23 to 25, we exper…
  • of our forecasting challenges growing 8% in the first half of 2026. We are clearly in the …
  • growth and kind of pushing off the bottom in 27 as we enter 28. And the high level formula…
  • you
  • know, potentially below our WAMGAR, but solid growth, and growth above our Whamger in 29, …
  • our
  • biggest segment as you look at 2028 will be our interventional cardiology, vascular, and p…
  • as
  • Penumbra goes organic and they continue to derive excellent momentum.
  • And
  • with a very strong portfolio cadence in that business, with our IVL platforms and peripher…
  • and
  • a strong cadence of imaging capabilities as well as launches within our VT IOE platform. S…
  • this quarter in our geology business.
  • We
  • expect our med surge segment businesses to essentially grow at our market whamger or grow …
  • defibrillator platform, which we expect uh CRM will comfortably return to growth in 2028 t…
  • And
  • then in Watchmen, we will anniversary a competitive launch in 2028. We'll be in the midst …
  • change ideally by 2028. So we see the watchman business kind of maximum down is in 2027 an…
  • launch, our full full year of Ferapulse Ultra, and pending approval or flex uh business. S…
  • profile of rhythm in 28, whereas 2027, that segment's driving uh the challenges.

Speaker 0

Thank you. The next question comes from Joanne Wench with City. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Joanne Wench with City. Please go ahead.

Speaker 1

Good morning, and thank you for taking the questions. Two parts. One part is internally, it sounds like you're doing quite a bit to build the bridge between today and 2028, which ?could include any number of things, such

Passages & reports (3)
  • Good morning, and thank you for taking the questions. Two parts. One part is internally, i…
  • could include
  • any number of things, such

Speaker unclear

?as

Passages & reports (1)
  • as

Speaker 6

Unverified voice label

Salesforce realignment, expense reduction, et cetera, et cetera. Could you please address what you're doing internally to build that bridge? And then second of all, the numbered delay, is there a way to share the steps to that resolution? And thank

Passages & reports (1)
  • Salesforce realignment, expense reduction, et cetera, et cetera. Could you please address …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Sure. We're certainly, and John, you can comment a bit more. As you would expect, we're aligning our cost structure to our reality of what we see in fourth quarter in 2027. So the team has gotten ahead of that about six months ago and are implementing a pretty um ?uh meaningful restructuring program, um both in terms of you know where we are discretionary spend, ?uh headcount, we want to uh de-layer the company a bit more, increase some of the spans and layers in the organization, and uh get after some SGA uh offsets.

So uh that program is very much in flight. Importantly, we re-maintain
?the really important cultural values of Boston Scientific that makes it a special place to work and focus on advancing science for life and our winning spirit. So we believe we will continue to drive a important culture within Boston Scientific focused on the future, despite the needed restructuring initiatives. Importantly, while we're doing that, we're also continuing to invest in these big growth platforms that will drive the company's growth back to decent growth in 28 ?and above market Whamgur and entering all these new markets that we're uh taking on.

So I think it's important that uh we show the discipline to drive those cost savings and uh invest our growth drivers at the same
?time. Yeah, Joanne, I I just add um with the

Passages & reports (12)
  • Sure. We're certainly, and John, you can comment a bit more. As you would expect, we're al…
  • uh
  • meaningful restructuring program, um both in terms of you know where we are discretionary …
  • uh
  • headcount, we want to uh de-layer the company a bit more, increase some of the spans and l…
  • the
  • really important cultural values of Boston Scientific that makes it a special place to wor…
  • while we're doing that, we're also continuing to invest in these big growth platforms that…
  • and
  • above market Whamgur and entering all these new markets that we're uh taking on. So I thin…
  • time. Yeah,
  • Joanne, I I just add um with the

Speaker 3

restructuring program, I'll fill in a couple pieces there. So anticipate to achieve over 500 million of savings from the program uh over the next three years. Uh ?been some tough decisions, uh, but I've been very pleased with how we've been tracking. We're a little ahead of where I thought we'd be at this point um with in the program. I expect to achieve over half of those savings exiting 2027.

So back to Larry's question,
?you know, that contributes to our confidence in 2028. Mike went through the top line, but from an EPS perspective as ?well. Program itself, focus on streamlining orb structures, back office transformation to streamline our processes, leverage shared services. There's a supply chain optimization, looking across our global supply network to better leverage technology, AI, and streamline across supply chain, and then a broader initiative just looking at other pools of spend like TE meetings, like use of external vendors to reduce our spend there.

So it's uh a very broad initiative, uh, but very focused. And um again, I've
?been pleased uh with how we've been tracking. We're a little ahead of our uh of schedule ?there. And sorry, Joanne, on the uh penumbra

Passages & reports (12)
  • restructuring program, I'll fill in a couple pieces there. So anticipate to achieve over 5…
  • been
  • some tough decisions, uh, but I've been very pleased with how we've been tracking. We're a…
  • you
  • know, that contributes to our confidence in 2028. Mike went through the top line, but from…
  • well.
  • Program itself, focus on streamlining orb structures, back office transformation to stream…
  • supply chain, and then a broader initiative just looking at other pools of spend like TE m…
  • been
  • pleased uh with how we've been tracking. We're a little ahead of our uh of schedule
  • there. And
  • sorry, Joanne, on the uh penumbra

Speaker 2

uh comments, maybe maybe some good and bad news. Um we're super impressed with the uh Penumber results uh for 2026. And the good news is uh with a bit of an extended closing period, we've continued to get to know the Penumber Trim extremely well, ?uh, how they run the business, uh, the synergies that are very obvious on growth side and some on the cost side when you combine two powerful businesses with interventional cardiology of Ashford and the Penumber business.

So we're very bullish on the Penumber team, uh, the progress, the innovation pipeline they have, and how they
will uh work very seamlessly within Boston Scientific to drive uh ongoing strength strength in Penumbra and our ICBT business. And the regulatory process has taken a bit of time. Um we're still very confident in closing the transaction, but based on some of the discussions with the uh ?uh regulatory authorities, we anticipate an early first quarter uh close.

Passages & reports (6)
  • uh comments, maybe maybe some good and bad news. Um we're super impressed with the uh Penu…
  • uh,
  • how they run the business, uh, the synergies that are very obvious on growth side and some…
  • will uh work very seamlessly within Boston Scientific to drive uh ongoing strength strengt…
  • uh
  • regulatory authorities, we anticipate an early first quarter uh close.

Speaker 0

Thank you. The next question comes from Rick Wise with Stiefle. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Rick Wise with Stiefle. Please go ahead.

Speaker 2

Good morning. Mike, ?I was hoping maybe you ?could uh further unpack the med surge outlook a little bit. You said, I think just a moment ago, you expected that the combined business to grow mid-single digits sort of in line with uh the Wandware uh market growth. Uh but it maybe talk

Passages & reports (5)
  • Good morning. Mike,
  • I was hoping maybe
  • you
  • could
  • uh further unpack the med surge outlook a little bit. You said, I think just a moment ago,…

Speaker unclear

?us

Passages & reports (1)
  • us

Speaker 7

Unverified voice label

through each piece. ?Uh uh Historically, these are

Passages & reports (3)
  • through each piece.
  • Uh
  • uh Historically, these are

Speaker unclear

?businesses

Passages & reports (1)
  • businesses

Speaker 2

that in totality grew seven or ?eight percent.

Passages & reports (3)
  • that in totality grew seven or
  • eight
  • percent.

Speaker 7

Can't you know why can't ?we dream ?or aspire

Passages & reports (5)
  • Can't you know why can't
  • we
  • dream
  • or
  • aspire

Speaker unclear

?for you

Passages & reports (1)
  • for you

Speaker 2

to get ?back to that kind of range? ?And maybe what needs to happen in in urology and endoscopy and neuro to get back there? And what are the key drivers here as as we look ahead to the next year or two? Thank ?you. Yes, I would agree. Uh you know, five to six mid single digit growth is not what we want med surge to be and not what it's been and not what it the potential is.

Um, just to break through the three of them really quickly, neuromodulation is doing very well. Our brain franchise is
doing well. We've really diversified our pain business into more minimally invasive uh alternatives in addition to spinal cord stem. And we continue to have additional uh growth drivers in that business with a whole new SCS launch that'll happen in 2028. So, overall, I would assume kind of over a period of time, the Neuromod business will continue to be accretive to the MedSERS growth profile.

Our endo business is very strong. We've got a list of quite a few product launches in that area with scopes and our versatile platform and a number number of others. The headwind in 2027 for endo is China.

Passages & reports (9)
  • to get
  • back
  • to that kind of range?
  • And
  • maybe what needs to happen in in urology and endoscopy and neuro to get back there? And wh…
  • you.
  • Yes, I would agree. Uh you know, five to six mid single digit growth is not what we want m…
  • doing well. We've really diversified our pain business into more minimally invasive uh alt…
  • Neuromod business will continue to be accretive to the MedSERS growth profile. Our endo bu…

Significant pricing erosion we will see in our China business in 2027. So the endo will anniversary that China pricing impact in fourth quarter 2027. So we expect you know kind of our endo business to be that mid-single digit growth range in 27, accelerate in 28 based on launching and uh getting flapping that um that China piece. The you know the challenge, quite frankly, has been urology.

And we've been we've been wrong on on calling the uh the growth trend in urology. Obviously, a lot of efforts are going on in that area.

Passages & reports (2)
  • Significant pricing erosion we will see in our China business in 2027. So the endo will an…
  • 27, accelerate in 28 based on launching and uh getting flapping that um that China piece. …

So we expect the urology business to improve in 2027, not back to its previous levels, but certainly not ?at a negative growth profile that we see in 2026. And this business is all about people and portfolio. We just announced in my uh in our script there we've got three stone launches that are three stone approvals, which has been the one segment that's been uh uh lagging the growth for that that franchise.

So we expect our core stone business to improve in 2027. And as you know, you've heard for many quarters now, we've struggled a bit with the axonyx integration. We've done great with the Silk Rodak uh integration with the NALU integration, but we've struggled with uh axonyx based on significant commercial turnover. We've done
a lot to hire a lot of new reps and clinical people in that area.

It takes a bit of time for them to get seasoned in their territories. But we expect to see improvement in that in 2027. So, in short, you know, 27, we think uh Euro will be in that kind of
lower to mid single digit range and neuro slightly higher. And endo and euro both lapping significant China BBP pricing in fourth quarter 27 to have a stronger 28.

But we overall we do aim to get back to kind of that seven to eight-ish numbers that we used to

Passages & reports (6)
  • So we expect the urology business to improve in 2027, not back to its previous levels, but…
  • at
  • a negative growth profile that we see in 2026. And this business is all about people and p…
  • So we expect our core stone business to improve in 2027. And as you know, you've heard for…
  • a lot to hire a lot of new reps and clinical people in that area. It takes a bit of time f…
  • lower to mid single digit range and neuro slightly higher. And endo and euro both lapping …

Speaker unclear

?see.

Passages & reports (1)
  • see.

Speaker 0

Thank you. The next question comes from Travis Steed with Bank of America. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Travis Steed with Bank of America. Please go ahead…

Speaker 2

Hey, thanks

Passages & reports (1)
  • Hey, thanks

Speaker 4

for the question. I wanted to ask on

Passages & reports (1)
  • for the question. I wanted to ask on

Speaker 5

the pipeline. There was a lot of things kind of across the board pushed out. Is is there something bigger picture going on on the pipeline? I could de-risking the pipeline. And also, John, you mentioned better forecasting abilities. So just curious if you can elaborate on that as well. Thanks a

Passages & reports (1)
  • the pipeline. There was a lot of things kind of across the board pushed out. Is is there s…

Speaker unclear

?lot. Yeah,

Passages & reports (1)
  • lot. Yeah,

Speaker 3

Travis, I'll I'll start on um the forecasting question and then uh turn to Mike and Joe's in the room here to go through the pipeline. Uh ?yeah, 2026 has been ?a challenging year for us, uh, ?As Mike said, after several years of exceptional growth, driven in large part by EP and Watchmen, we've seen that cycle turn. So we're in a tough business cycle now because of the dynamics predominantly within those two businesses.

And we've struggled to forecast that this year. And we need to be better.
I recognize

Passages & reports (8)
  • Travis, I'll I'll start on um the forecasting question and then uh turn to Mike and Joe's …
  • yeah,
  • 2026 has been
  • a
  • challenging year for us, uh,
  • As
  • Mike said, after several years of exceptional growth, driven in large part by EP and Watch…
  • I recognize

Speaker 2

that.

Passages & reports (1)
  • that.

Speaker unclear

?Joe

Passages & reports (1)
  • Joe

Speaker 3

knows that. The whole team here knows ?that. We feel we've got a clearer picture of the business dynamics now. We've laid that ?out. We're taking action with the restructuring program. We have our new operating model, which will drive greater focus,

Passages & reports (5)
  • knows that. The whole team here knows
  • that.
  • We feel we've got a clearer picture of the business dynamics now. We've laid that
  • out.
  • We're taking action with the restructuring program. We have our new operating model, which…

Speaker 2

greater speed, greater accountability. And from a forecasting ?process perspective, we've made a number of enhancements, implemented more sensitivity

Passages & reports (3)
  • greater speed, greater accountability. And from a forecasting
  • process
  • perspective, we've made a number of enhancements, implemented more sensitivity

Speaker 3

and scenario analysis, more objective models, more third party

Passages & reports (1)
  • and scenario analysis, more objective models, more third party

Speaker 2

data that we pull ?in. So we feel with all of that together, uh,

Passages & reports (3)
  • data that we pull
  • in.
  • So we feel with all of that together, uh,

Speaker 3

you'll see improved forecasting accuracy from us on a go forward basis. And um, you ?know, with the guidance uh that we put forth for ?the fourth quarter here and uh the framework for 2027, uh very, very focused on delivering on on ?that. Like uh Joe Pipeline.

Passages & reports (7)
  • you'll see improved forecasting accuracy from us on a go forward basis. And um, you
  • know,
  • with the guidance uh that we put forth for
  • the
  • fourth quarter here and uh the framework for 2027, uh very, very focused on delivering on …
  • that. Like
  • uh Joe Pipeline.

Speaker 2

Maybe just the quick things, you know, uh we pride ourselves in executing 26 has not been the year we've executed so well. So we're we've done a lot to um to tighten our performance. John just went through some of our forecasting areas. Um, in terms of the overall business, though you know the business has gotten uh larger. So one of the reasons for the um for Joe now becoming COO and breaking into sectors is to have even more focus on these sectors so we improve our efficiency and reliability in terms of the dates that we give ?you uh for these big launches.

We do have a very impressive pipeline uh that's coming for the company. Uh we're we're down for a bit, but we're far from out. And these pipeline products will come through
?and return Boston Scientific to its high performance reputation that we want to earn back with ?you. Some of these products are complicated with clinical trials and regulatory processes. ?So we've kind of seen about a six month delay in some of these big platforms.

We want to make sure we launch them at high scale with high quality. And we aim to do that. But the pipeline is very rich,
?and we can go through some of those elements, or Joe can provide more detail. But we're not happy with some of these slips. We're we're uh put a lot of focus on it, and we know the impact that it has in the business.

Passages & reports (12)
  • Maybe just the quick things, you know, uh we pride ourselves in executing 26 has not been …
  • business has gotten uh larger. So one of the reasons for the um for Joe now becoming COO a…
  • you
  • uh for these big launches. We do have a very impressive pipeline uh that's coming for the …
  • and
  • return Boston Scientific to its high performance reputation that we want to earn back with
  • you.
  • Some of these products are complicated with clinical trials and regulatory processes.
  • So
  • we've kind of seen about a six month delay in some of these big platforms. We want to make…
  • and
  • we can go through some of those elements, or Joe can provide more detail. But we're not ha…

Speaker 0

Thank you. The next question comes from Josh Jennings with TD Cowan. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Josh Jennings with TD Cowan. Please go ahead.

Speaker unclear

?Good

Passages & reports (1)
  • Good

Speaker 5

morning. Thanks for taking the questions. Uh Mike, I was hoping to just clarify um just the outlook for the WAMGRA as as

Passages & reports (1)
  • morning. Thanks for taking the questions. Uh Mike, I was hoping to just clarify um just th…

Speaker unclear

?you've given

Passages & reports (1)
  • you've given

Speaker 7

strong high uh good high color, high level color on uh 27 and 28. You know, 2026 Whamgur is seven percent. Is you got some pipeline products potentially could expand, but is the assumption w baked into some of your high level color in the out years that that that Whamgur is is sustainable at that seven percent level? And ?then just a side question,

Passages & reports (4)
  • strong high uh good high color, high level color on uh 27 and 28. You know, 2026 Whamgur i…
  • that seven percent level? And
  • then
  • just a side question,

Speaker 5

maybe just uh hoping to get an updated outlook

Passages & reports (1)
  • maybe just uh hoping to get an updated outlook

Speaker unclear

?on

Passages & reports (1)
  • on

Speaker 7

your view of the uh the the the mark of US EP market and and and growth there ?uh as we move into twenty seven and twenty eight. Thanks for taking the question.

Passages & reports (3)
  • your view of the uh the the the mark of US EP market and and and growth there
  • uh
  • as we move into twenty seven and twenty eight. Thanks for taking the question.

Speaker 3

Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

and on the Whamgar, uh ?we don't ?we're not used to growing below our

Passages & reports (5)
  • and on the Whamgar, uh
  • we
  • don't
  • we're
  • not used to growing below our

Speaker 3

Whamgur. Uh

Passages & reports (1)
  • Whamgur. Uh

Speaker 2

we think it's still about 7%. We've seen some pressure overall in maybe the uh Euro market uh and endo markets that have pushed it down a bit uh to that seven percent level. EP market continues to remain very strong. Obviously the Watchman market has pulled that Whamgir

Passages & reports (1)
  • we think it's still about 7%. We've seen some pressure overall in maybe the uh Euro market…

Speaker 3

to that seven percent range, but the Watchman market's about a two billion market uh overall. Importantly, as you look at the LRP, we're entering markets that grow faster than our whamger. The IBL market, potentially the hypertension market,

Passages & reports (1)
  • to that seven percent range, but the Watchman market's about a two billion market uh overa…

Speaker 2

and some big launches in EP and segments that

Passages & reports (1)
  • and some big launches in EP and segments that

Speaker 3

we don't play in today with ICE and also with Ferroflex.

Passages & reports (1)
  • we don't play in today with ICE and also with Ferroflex.

Speaker 2

So I

Passages & reports (1)
  • So I

Speaker unclear

?think

Passages & reports (1)
  • think

Speaker 3

overall, ?kind of that 7%

Passages & reports (3)
  • overall,
  • kind
  • of that 7%

Speaker 2

whamger today, and then that seven to maybe, and then you're adding Penumbra, which is at scale, a creative whamger to the business, or at least in line. ?So I think that kind of 7% range now and maybe seven to eight over the next three

Passages & reports (3)
  • whamger today, and then that seven to maybe, and then you're adding Penumbra, which is at …
  • So
  • I think that kind of 7% range now and maybe seven to eight over the next three

Speaker 3

years is about the right uh way to call ?it. Um

Passages & reports (3)
  • years is about the right uh way to call
  • it.
  • Um

Speaker 2

when we look at twenty seven based on the comments that we made, you know, it's or I'm sorry, when we look at twenty seven, obviously growing below the Wamgar based on the uh comments that we made. And then twenty eight, we aim to get back to uh closer to those Whamgar numbers and beyond.

Passages & reports (2)
  • when we look at twenty seven based on the comments that we made, you know, it's or I'm sor…
  • beyond.

Speaker 0

Thank you. The next question comes from Marie Thibault ?with US Bank BTIG. Please go ahead.

Passages & reports (3)
  • Thank you. The next question comes from Marie Thibault
  • with
  • US Bank BTIG. Please go ahead.

Speaker unclear

?Hi

Passages & reports (1)
  • Hi

Speaker 6

there. Uh wanted to circle back

Passages & reports (1)
  • there. Uh wanted to circle back

Speaker unclear

?to the commentary on no growth for

Passages & reports (1)
  • to the commentary on no growth for

Speaker 2

2027 when it comes to EPS.

Passages & reports (1)
  • 2027 when it comes to EPS.

Speaker 7

We heard John talk ?about some of the restructuring efforts that are being put in place. I know ?this quarter you were able to offset,

Passages & reports (5)
  • We heard John talk
  • about some
  • of the restructuring efforts that are being put in place. I know
  • this quarter you were
  • able to offset,

Speaker unclear

?you know, things like expedited shipping costs related to the cyber attack.

Passages & reports (1)
  • you know, things like expedited shipping costs related to the cyber attack.

Speaker 7

You were able to uh offset some of that with with better OpEx ?control. Um so thinking about all of this, um

Passages & reports (3)
  • You were able to uh offset some of that with with better OpEx
  • control. Um
  • so thinking about all of this, um

Speaker 6

when we

Passages & reports (1)
  • when we

Speaker unclear

?think about no growth and

Passages & reports (1)
  • think about no growth and

Speaker 1

adjusted EPS next year, is it really about product ?mix and some of those less profitable products being ?the contributors to sales growth, or

Passages & reports (5)
  • adjusted EPS next year, is it really about product
  • mix
  • and some of those less profitable products being
  • the contributors
  • to sales growth, or

Speaker unclear

?why else shouldn't we expect um some adjusted

Passages & reports (1)
  • why else shouldn't we expect um some adjusted

Speaker 7

EPS growth given some of the uh efforts you're putting in place? Thanks for taking the question.

Passages & reports (1)
  • EPS growth given some of the uh efforts you're putting in place? Thanks for taking the que…

Speaker 3

Mix is the biggest factor, uh, Marie. So you know, as we talked about um, ?do you see pressure on on the top line? That pressure predominantly is with watchmen and EP. So we'll feel the mixed impact of that within gross margin. And then with the China pricing pressure that we see escalating, that will also impact gross margin in 2027 as well. ?And we do have some investment that we continue to make across supply chain, our quality systems.

So as you look ahead to 2027, and we'll give
?the guide and all the detail in the Q4 earnings call, ?but expect significant pressure and gross margin next year. ?And we'll continue to invest in the portfolio. We have a lot that we're excited about in the portfolio and want to make sure we're fully funding uh those initiatives. ?Uh now again, we will have restructuring uh that will help to offset um uh some of those costs.

We'll continue to be very disciplined with spend in 2027.
?Uh but as you put that all together, ?and I'd expect our EPS next year to be roughly in line with with revenue. And again, um uh on our commentary uh expect to be challenged to grow next

Passages & reports (18)
  • Mix is the biggest factor, uh, Marie. So you know, as we talked about um,
  • do
  • you see pressure on on the top line? That pressure predominantly is with watchmen and EP. …
  • impact gross margin in 2027 as well.
  • And
  • we do have some investment that we continue to make across supply chain, our quality syste…
  • the
  • guide and all the detail in the Q4 earnings call,
  • but
  • expect significant pressure and gross margin next year.
  • And
  • we'll continue to invest in the portfolio. We have a lot that we're excited about in the p…
  • Uh
  • now again, we will have restructuring uh that will help to offset um uh some of those cost…
  • Uh
  • but as you put that all together,
  • and
  • I'd expect our EPS next year to be roughly in line with with revenue. And again, um uh on …

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 0

Thank you. The next question comes from Pito Chickering with Deutsche Bank. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Pito Chickering with Deutsche Bank. Please go ahea…

Speaker 5

Can you talk about what's causing ?the delay ?of the Thrive data and therefore the Vivius launch and on Vitalist? ?I think you said you weren't looking at high risk PCI.

Passages & reports (7)
  • Can you talk about what's causing
  • the
  • delay
  • of the
  • Thrive data and therefore the Vivius launch and on Vitalist?
  • I
  • think you said you weren't looking at high risk PCI.

Speaker 2

Can you talk about what you're seeing with the product and do you think the market is still attractive

Passages & reports (1)
  • Can you talk about what you're seeing with the product and do you think the market is stil…

Speaker unclear

?with just shock? Thanks. Yeah,

Passages & reports (1)
  • with just shock? Thanks. Yeah,

Speaker 3

Pito, it's Ken. Maybe let me start with Vitalist. So, you know, there was data from a competitor Ruiz last year, ?you know, that I think called into question the broad use of mechanical circulatory support for high-risk PCI. We still believe that there is a role for that therapy there, but we do, I think, as a field, need to figure out better patient selection.

Passages & reports (3)
  • Pito, it's Ken. Maybe let me start with Vitalist. So, you know, there was data from a comp…
  • you
  • know, that I think called into question the broad use of mechanical circulatory support fo…

The pivot to first studying cardiogenic shock, I think it's very important to realize just how much of an unmet medical need there is in AMI cardiogenic shock. There is still mortality approaching 50% in patients who present with acute MI and shock, and it occurs in up to 10% of patients who are having ST elevation MI. Data was presented a couple of years ago.

The danger shock trial showed beyond a doubt that mechanical circulatory support can reduce mortality in those patients. So, you know, this is both an area of major need and an area where we know that
mechanical circulatory support can improve outcomes. And you know, we believe that with our Vitalist platform, we have differentiated advantages over the current incumbent in terms of dealing with shock.

Uh, Vitalist has a uh a novel catheter design that improves positional stability, that's particularly
important in dealing with shock patients, ?where the catheter needs to stay in place in the CCU ?for a longer period of time, along with strategies aimed at just minimizing the complexity of managing these patients and minimizing vascular complications. And so that's why we're so excited about the potential for the Vitalist platform.

And why actually we we we like the move into
AMI shock as the first trial.

Passages & reports (9)
  • The pivot to first studying cardiogenic shock, I think it's very important to realize just…
  • 10% of patients who are having ST elevation MI. Data was presented a couple of years ago. …
  • mechanical circulatory support can improve outcomes. And you know, we believe that with ou…
  • important in dealing with shock patients,
  • where
  • the catheter needs to stay in place in the CCU
  • for
  • a longer period of time, along with strategies aimed at just minimizing the complexity of …
  • AMI shock as the first trial.

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 1

then on Thrive.

Passages & reports (1)
  • then on Thrive.

Speaker unclear

?On

Passages & reports (1)
  • On

Speaker 3

Thrive, uh really, again, it's just a matter of uh continued execute on enrollment in the clinical trial. Uh enrollment uh I think frankly has been a little bit slower than we would have hoped as we navigated the transition and the integration of the Salama V team into the Boston scientific ecosystem. Uh but again, you know, are are are confident that we can get that on track and that we will eventually uh uh finish enrollment in the trial.

Um believe in the technology. We do believe that ultrasound is uh the best for the energy sources that we can use for doing renal denervation,
and we continue to believe that the uh Thrive platform has differentiated advantages over the two current approved devices for uh renal denervation for hypertension.

Passages & reports (3)
  • Thrive, uh really, again, it's just a matter of uh continued execute on enrollment in the …
  • again, you know, are are are confident that we can get that on track and that we will even…
  • and we continue to believe that the uh Thrive platform has differentiated advantages over …

Speaker 0

Thank you. The next question comes from Matthew O'Brien with Piper Sandler. Please go ahead.

Passages & reports (1)
  • Thank you. The next question comes from Matthew O'Brien with Piper Sandler. Please go ahea…

Speaker unclear

?Just to follow up on the pushback on

Passages & reports (1)
  • Just to follow up on the pushback on

Speaker 5

the on the pipeline, because that's what we're all kind of banking on at this point, is the pipeline coming through. Um, you just you just mentioned um you know Tybus and what's happening there, but with Ultra and with Flex, is it product related? Is it enrollment? Is it manufacturing? What's what's slowing things down in terms of getting those ?uh to market and then just anything more you can provide on Penumbra and the and the modest push on the timing there?

Is it is it more regulatory questions, specific product related questions, just anything on those things? Thanks so

Passages & reports (4)
  • the on the pipeline, because that's what we're all kind of banking on at this point, is th…
  • down in terms of getting those
  • uh
  • to market and then just anything more you can provide on Penumbra and the and the modest p…

Speaker unclear

?much. Yeah,

Passages & reports (1)
  • much. Yeah,

Speaker 3

we won't provide any more uh updates on Penumbra other than what I commented on. We're very bullish on the transaction

Passages & reports (1)
  • we won't provide any more uh updates on Penumbra other than what I commented on. We're ver…

Speaker 2

and we're we're aiming to close that as early as we can. We'll likely it'll be pushing into uh early twenty seven. In terms of the some of the product delays, Joe's here. Joe, you can add some comments to the one I made. I'll take uh Ultra first. As you know, Ultra uh is a PMA supplement, does not require a clinical study. So most of the issues we have there are just on getting through what we call uh design verification and validation.

And
?if you look at Ultra, that's a hardware, software, and a catheter project. So the let's call it one quarter delay that you see is just a a summary ?of issues that we have to work through with DV has nothing to ?do with anything on a on a on the clinical trial because we don't need clinical data to get Ultra approved. On Ferriflex, I would call it three things.

It is related to our negotiations with FDA on getting the actual IDE
approved. We've had slight delays with CMS full approval, and there and there are some operational challenges getting everything that's needed to to complete a FairFlex case done to expand the number of sites. So we believe we will have that largely we just got CMS and we believe our supply chain to support the study will be pretty robust by end of year.

So I think when we get on the Q4 call, a good question for us will be how is enrollment going in the FairFlex study, which we expect that to ramp each successive week and month going
forward.

Passages & reports (11)
  • and we're we're aiming to close that as early as we can. We'll likely it'll be pushing int…
  • a PMA supplement, does not require a clinical study. So most of the issues we have there a…
  • if you
  • look at Ultra, that's a hardware, software, and a catheter project. So the let's call it o…
  • of
  • issues that we have to work through with DV has nothing to
  • do
  • with anything on a on a on the clinical trial because we don't need clinical data to get U…
  • approved. We've had slight delays with CMS full approval, and there and there are some ope…
  • and we believe our supply chain to support the study will be pretty robust by end of year.…
  • forward.

Speaker 0

Thank you. I understand there's time for one last question. ?Uh that would be from Matt Taylor with Jeffries. Please go ahead.

Passages & reports (3)
  • Thank you. I understand there's time for one last question.
  • Uh
  • that would be from Matt Taylor with Jeffries. Please go ahead.

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 7

right, thanks for

Passages & reports (1)
  • right, thanks for

Speaker unclear

?taking the

Passages & reports (1)
  • taking the

Speaker 5

question. Um I I wanted to follow up on the number, not the timing, ?but could you talk about the kind of growth that you expect from that that platform? And before you had said in the first year it could be six to eight cents uh dilutive, but you know, some of the math there has changed I was wondering if you could update us on ?on that at all.

It's it's decelerated a little bit in the um last couple quarters so
?just wanted to get an update.

Passages & reports (7)
  • question. Um I I wanted to follow up on the number, not the timing,
  • but
  • could you talk about the kind of growth that you expect from that that platform? And befor…
  • on
  • that at all. It's it's decelerated a little bit in the um last couple quarters so
  • just
  • wanted to get an update.

Speaker 3

Yeah uh thanks Matt I'll I'll take the dilution piece and then um maybe Mike and Joe can give quick comments on the growth profile. But um ?yeah we're excited to add penumbra uh you can see from their results they're uh performing uh very well high growth ?uh would be a great addition um to our cardiovascular portfolio So we announced Penumbra in mid-January.

We anticipate uh closing in uh early 2027 at this point. At the time of announcement, uh we had uh said we expected six to eight cents uh of
dilution. That assumes uh no divestures, that assumes interest rates that were in place um at that time. ?Uh we have seen uh increases in uh interest rates since then, so that um uh will drive um uh incremental financing costs and um I think we'll put uh additional pressure on the uh EPS solution that we'd expect.

But once we close the deal, uh we'll provide much more detail.

Passages & reports (8)
  • Yeah uh thanks Matt I'll I'll take the dilution piece and then um maybe Mike and Joe can g…
  • yeah
  • we're excited to add penumbra uh you can see from their results they're uh performing uh v…
  • uh
  • would be a great addition um to our cardiovascular portfolio So we announced Penumbra in m…
  • dilution. That assumes uh no divestures, that assumes interest rates that were in place um…
  • Uh
  • we have seen uh increases in uh interest rates since then, so that um uh will drive um uh …

Speaker 1

Thanks so much, Sean. Thank you for joining us today. We appreciate your interest in Boston Scientific. If we were unable to get to your question or if you have any follow ups, please don't hesitate to reach out to investor the investor relations team. Before you disconnect, Drew will give you all of the pertinent details for the replay. Thanks,

Passages & reports (2)
  • Thanks so much, Sean. Thank you for joining us today. We appreciate your interest in Bosto…
  • pertinent details for the replay. Thanks,

Speaker 0

Thank you. Please note a recording will be available in one hour by dialing either 1-877-344-7529 or 1-412-317-0088 using replay code 850-6317 until November 11th, 2026 ?at 1159 p.m. Eastern Time. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Passages & reports (4)
  • Thank you. Please note a recording will be available in one hour by dialing either 1-877-3…
  • until November 11th, 2026
  • at
  • 1159 p.m. Eastern Time. The conference has now concluded. Thank you for attending today's …
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

2 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 2. Unassigned words: 321. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T20:15:29.939Z.
Transcript version v1-4895a05957d6c0c93720 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.